Malaria is a leading cause of death and disease within the developing world affecting people who live in tropical climates the most. Reports from the World Health Organization in 2004 estimate that within 107 at-risk countries, 350-500 million cases of malaria occur each year. A large majority of human infections are caused by the parasite Plasmodium falciparum. Of the over 3 billion people living in at-risk countries, over a million die each year from malarial infections. Over the years malaria treatments have been developed to target the lifecycle of the P. falciparum malaria parasite in the blood stage of development. Classical treatments have, for the most part, met with resistance throughout infected regions, and new treatments are needed. Artemisinin is a natural product from a Chinese plant that has been known for centuries to have antimalarial activity and has shown little to no resistance in modern usage. Short half-life coupled with poor bioavailability has prompted the search for a more potent artemisinin-based drug. We have developed dimers of C-10 carbon linked artemisinin units that have been shown to completely cure infected mice with one single dose at 30 mg/kg subcutaneously. To the best of our knowledge, no artemisinin-based drugs or synthetic trioxanes have been reported with potency close to that of our dimer compounds. In addition, several of our dimer compounds have also shown highly potent activity when administered orally. Here we report on the chemistry and biological activity of some of these dimeric compounds.